ColoPlus, A New Product Based On Bovine Colostrum, Alleviates HIV-associated Diarrhoea

この研究の注釈:

In HIV-infected persons with associated diarrhea, a colostrum containing porridge known as ColoPlus (32% colostrum, where each 50g pack contained 2-4g immunoglobulins and is taken twice daily) for four weeks was able to greatly reduce daily bowel movements from 7 down to 1.6, the benefit lasting for an additional two weeks after supplement cessation.

It was noted that CD4+ lymphocytes increased in all persons, to a larger degree in those with less than 200 cells per microliter (experiencing a 94-110% increase) and that fatigue associated with HIV was reduced 81%.


Lack Of Prophylactic Efficacy Of An Enteric-coated Bovine Hyperimmune Milk Product Against Enterotoxigenic Escherichia Coli Challenge Administered During A Standard Meal

この研究の注釈:

Supplementation of colostrum (immunized against E.coli) in enteric capsules failed to exert protective effects against E.coli-induced diarrhea relative to placebo.


Randomized Control Trials Using A Tablet Formulation Of Hyperimmune Bovine Colostrum To Prevent Diarrhea Caused By Enterotoxigenic Escherichia Coli In Volunteers

この研究の注釈:

400mg of immunized bovine colostrum given to participants prior to a meal (and with this meal, E.coli infection to induce diarrhea) and twice daily at other times appears to reduce diarrhea as well as intestinal pain related to the diarrhea relative to placebo; overall amount of E.coli recovered in the feces was not altered.


Treatment Of Severe Diarrhea Caused By Cryptosporidium Parvum With Oral Bovine Immunoglobulin Concentrate In Patients With AIDS

この研究の注釈:

21 days supplementation of colostrum in persons with HIV/AIDS associated diarrhea (no placebo control) noted significant reductions in stool weight and frequency associated with powdered colostrum () but not encapsulated colostrum (), with the reduction seen with powdered colostrum being from 6.6 defecations daily down to 5.4.

Patients not infected by Cryptosporidium parvum did not experience benefit from powdered colostrum.


Treatment Of Diarrhoea In Human Immunodeficiency Virus-infected Patients With Immunoglobulins From Bovine Colostrum

この研究の注釈:

In persons with diarrhea associated with immunodeficiency (most patients having HIV), supplementation of colostrum at 10g (product known as Lactobin) was able to significantly reduce stool frequency from 7.4 to 2.2 daily in responders, although some persons experienced no response and mostly reoccurred after four weeks supplement cessation.


Protection By Milk Immunoglobulin Concentrate Against Oral Challenge With Enterotoxigenic Escherichia Coli

この研究の注釈:

Supplementation of colostrum immunized against E.coli given 3.55g of the immunoglobulins thrice daily taken 15 minutes after meals for one week prior to being fed E.coli prevented diarrhea from E.coli ingestion despite diarrhea still occuring in the control group given the colostrum immunized against rotavirus. Total E.coli in the feces did not appear to be altered with immunized colostrum.


Protection By Milk Immunoglobulin Concentrate Against Oral Challenge With Enterotoxigenic Escherichia Coli

この研究の注釈:

Supplementation of colostrum immunized against E.coli given 3.55g of the immunoglobulins thrice daily taken 15 minutes after meals for one week prior to being fed E.coli prevented diarrhea from E.coli ingestion despite diarrhea still occuring in the control group given the colostrum immunized against rotavirus. Total E.coli in the feces did not appear to be altered with immunized colostrum.


Effect Of Bovine Colostrum-based Food Supplement In The Treatment Of HIV-associated Diarrhea In Northern Uganda: A Randomized Controlled Trial

この研究の注釈:

50g of a colostrum containing porridge (twice daily) for four weeks to persons with HIV-associated diarrhea for four weeks (and followed up for an additional five) significantly reduced stool frequency 79% (58% in controls given standard anti-diarrhea therapy) and increased CD4+ lymphocytes 14% despite a 12% decrease in control. Fatigue was reported to be reduced by 85% relative to baseline, greater than the 43% reduction seen with placebo.